| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | UNC1215 | GDSC1000 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | Nilotinib | FIMM | pan-cancer | AAC | -0.022 | 0.9 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | -0.0071 | 0.9 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | -0.007 | 0.9 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | 0.0095 | 0.9 |